Sun Pharma Introduces CEQUA in India, Offering New Hope for Dry Eye Disease Patients

In April 2023, Sun Pharmaceutical Industries Ltd, a leading Indian multinational pharmaceutical company, has announced the launch of CEQUA in India, a novel therapy for the treatment of Dry Eye Disease (DED).

CEQUA (Cyclosporine Ophthalmic Solution) 0.09% is a patented, innovative formulation of cyclosporine A, an immunosuppressive agent used in ophthalmology for many years. The medication is indicated to increase tear production in patients with DED, a chronic condition affecting millions worldwide, causing discomfort, irritation, and visual disturbances.

CEQUA utilizes NCELL* Technology, an innovative delivery system that represents a significant advancement in the treatment of the chronic dry eye. The technology employs a specialized encapsulation that envelops the active ingredient, cyclosporine, allowing it to penetrate through the tear film layers and release it directly into the ocular tissues where it is most effective. Once released, CEQUA acts against inflammation, the root cause of chronic dry eye.

Sun Pharma's CEQUA is the first and only FDA-approved cyclosporine ophthalmic solution with nano micellar technology. This drug delivery system improves the bioavailability of the medication and ensures that the active ingredient reaches the target cells. The formulation is effective in clinical trials, improving both signs and symptoms of DED.

Dry Eye Disease (DED), known as keratoconjunctivitis sicca, affects millions of individuals worldwide. According to the National Eye Institute, DED occurs when there is an inadequate quantity and quality of tears to lubricate the eye’s surface properly. Patients with DED may experience discomfort, such as scratchiness or the feeling of a foreign object in the eye, as well as stinging, burning, watering, discharge, pain, and redness. The disease can cause inflammation and damage to the ocular surface.

Speaking about the launch, Mr. Abhay Gandhi, CEO of North America Sun Pharma, said, "Sun Pharma is committed to bringing innovative therapies to patients in India. CEQUA is a breakthrough treatment option for people with dry eye disease, and we are proud to make it available in India."

According to a report by the All India Ophthalmological Society, Dry Eye Disease affects approximately 15% of the Indian population, with the prevalence increasing with age. The launch of CEQUA is expected to provide a much-needed treatment option for millions of patients suffering from DED in India.

Sun Pharma is a global pharmaceutical company that develops and markets a wide range of innovative products and therapies across various therapeutic areas, including ophthalmology. The company has a strong presence in India and exports its products to over 100 countries worldwide.

For Info : [email protected]

Website : https://reportsandinsights.com